As of 2025-11-02, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (3.88) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.32 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -152.9%.
The range of the Relative Valuation is (3.52) - (4.38) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.8x - 28.7x | 24.3x |
| Forward P/E multiples | 19.0x - 25.8x | 21.4x |
| Fair Price | (3.52) - (4.38) | (3.88) |
| Upside | -148.2% - -159.8% | -152.9% |
| Date | P/E |
| 2025-10-31 | -43.15 |
| 2025-10-30 | -42.74 |
| 2025-10-29 | -43.10 |
| 2025-10-28 | -42.68 |
| 2025-10-27 | -43.10 |
| 2025-10-24 | -42.45 |
| 2025-10-23 | -42.39 |
| 2025-10-22 | -41.74 |
| 2025-10-21 | -41.18 |
| 2025-10-20 | -40.85 |
| 2025-10-17 | -39.09 |
| 2025-10-16 | -39.62 |
| 2025-10-15 | -40.15 |
| 2025-10-14 | -37.85 |
| 2025-10-13 | -41.50 |
| 2025-10-10 | -42.56 |
| 2025-10-09 | -42.74 |
| 2025-10-08 | -42.92 |
| 2025-10-07 | -40.97 |
| 2025-10-06 | -41.39 |
| 2025-10-03 | -42.15 |
| 2025-10-02 | -43.21 |
| 2025-10-01 | -43.45 |
| 2025-09-30 | -44.75 |
| 2025-09-29 | -44.51 |
| 2025-09-26 | -44.98 |
| 2025-09-25 | -45.10 |
| 2025-09-24 | -45.81 |
| 2025-09-23 | -46.10 |
| 2025-09-22 | -46.63 |
| 2025-09-19 | -45.39 |
| 2025-09-18 | -46.93 |
| 2025-09-17 | -45.39 |
| 2025-09-16 | -45.69 |
| 2025-09-15 | -45.39 |
| 2025-09-12 | -46.63 |
| 2025-09-11 | -47.58 |
| 2025-09-10 | -47.22 |
| 2025-09-09 | -47.63 |
| 2025-09-08 | -48.28 |
| 2025-09-05 | -48.75 |
| 2025-09-04 | -48.75 |
| 2025-09-03 | -48.87 |
| 2025-09-02 | -48.87 |
| 2025-08-29 | -48.99 |
| 2025-08-28 | -49.93 |
| 2025-08-27 | -50.23 |
| 2025-08-26 | -50.58 |
| 2025-08-25 | -49.46 |
| 2025-08-22 | -50.46 |